Oneview Healthcare PLC

Thank you for standing by and welcome to the OneView Healthcare half-year financial results. All participants are in a listen-only mode. There will be a presentation followed by a question and answer session. If you wish to ask a question, you will need to press the star key followed by the number 1 on your telephone keypad. If you wish to ask a question via webcast, please enter it into the ask a question box and click submit. I would now like to hand the conference over to Mr. James Fitter, CEO. Please go ahead.

Thanks, Ashley, and good morning to everyone in Australia. Good afternoon to those here in the United States, and good evening to those joining in Dublin, including Dara Lyons, our CFO, and Tony Pettit, our Company Secretary. As always, I'd just like to start with a reminder around the legal disclaimer and forward-looking statements and just a clarification that all the amounts we're going to refer to are in Euros. And a reminder, we are December year-end, so we are reporting the first half results for the six months ended June 2025. Any reference to the full year refers to the prior year of 2024. Just a reminder of our mission is to improve connected care experiences every day and our vision is really focused around redefining the digital environment of care to make it accessible, seamless and reliable for all and as always that mission continues to resonate with all of our employees and I think with all of our shareholders. Our footprint includes three of the hospitals that have been recognised in the top 20 in the United States. So joining me today, as I mentioned, is Dara, who's now 11 months with the company as Chief Financial Officer. So some of you will have met him on the full year results call earlier in the year. But welcome to Dara, who will be talking through the financial numbers in some detail. So unsurprisingly, we're going to talk through the financial results. We're going to talk about the innovative work we're doing on the product front, particularly around our AR strategy. Of course, we'll be providing commercial and sales updates. and of course the outlook for the balance of the year and hopefully leave plenty of time for questions. So let me start with the key highlights. I don't want to steal Dara's thumb, so I'm just going to point to a couple of these. The headline that I think will attract most attention is that total revenue is up 36% for the year, which is a very pleasing result given the revenue profile we've had in recent years. So delighted with that outcome. Added up further to many customer logos in the half year. And you'll note in this presentation we're referring to live endpoints, which is a reflection of the fact that our product portfolio has diversified to include not just bedside technology but dual signs and whiteboards. So a reference to an endpoint is a reference to any device in the patient room that is revenue generating, and Dara will talk through a little bit more around that. Cross-margin was down slightly in the first half as a function of the fact that we were delivering a substantial amount of hardware in line with the revenue growth. And on the following slide you're going to see the visualisation of the revenue over the last five years. What's most pleasing about this revenue growth is just the broad base of opportunities that we're working on in the first half of the year. Some of these have been customers for many years that are continuing to expand their footprint, which would include the likes of NYU Wangone, BJC Healthcare, University of Miami, but also a number of new logos that are now in flight in deployment mode and we talked a bit about speed of revenue and pace of deployment. But this sets us up very nicely for the second half and is a great foundation for the first year with some very significant customers that are continuing to be expanding in the second half of the year. In terms of investment highlights, efficiency is a key theme. We're moving, working, as I mentioned, towards faster and more efficient deployments. We'll talk about how we're doing that shortly, but obviously we're being AI-powered solutions across every business function in the business. We'll talk more about that in a second. You will have noted from the 4C that we have restructured our Australian and some other functional teams to better align our operations with current business opportunities where obviously cognitive of the challenges that the Australian market is facing, particularly when it comes to private hospitals. That's having an impact on both customer affordability for digital health solutions and, of course, on pricing as well. On the execution front, as I mentioned, we've added two new customer logos in the first half of the year. The sales pipeline is expanding really nicely, and I'll talk through that in some detail. And as we mentioned in the 4C, we just signed a very important three-year extension with a a very significant customer, which is going to deliver 20% year-on-year revenue growth from that customer loan, which is great to see that we have some pricing power. In terms of innovation, we are working on an entire rebuild of our front-end, which is probably the most significant rebuild we've done for some time. We've been running the same front-end user experience for the last dozen years, so this is a big change, something that's really been driven by customer feedback. and we're super excited about how that's panning out and we're going to talk to you a bit about how we're embedding AI engagement products into that work. And we're also going to talk about the bedrock of our AI strategy which of course is our ISO 42001 certification. For those of you who are not familiar, ISO 42001 is the international standard that specifies requirements for establishing, implementing, maintaining and of course continually improving an artificial intelligence management system within organizations. And we were the first, and I believe to this day, the only ASX company to have achieved that certification, and we are certainly the only one of our U.S. competitors to achieve that, which we're extremely proud of. So with that, let me pass it across to Dara, who will talk through the numbers in a bit more detail, and we'll come back and talk a bit more about the product innovation. Over to you, Dara.

Thanks James and good morning and good afternoon to you all on the line. So we had a very good first half of the year in terms of top line growth as James has mentioned with 36% growth in the first half of the year.